Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

December 10, 2023

https://www.globenewswire.com/news-release/2023/12/08/2793371/0/en/Onconova-Therapeutics-Preclinical-Narazaciclib-Data-at-SABCS-Highlights-Differentiated-Anti-Tumor-Activity-v-Other-CDK4-6i-s.html

Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved CDK4/6 inhibitors

Read more at globenewswire.com

Related news for (ONTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.